News | Radiopharmaceuticals and Tracers | May 17, 2019

New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent

Sixty-patient study will assess CellPoint’s Oncardia imaging agent for ability to evaluate presence, severity of coronary artery disease

New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent

May 17, 2019 — Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the company's new one-vial Oncardia (ethylenedicysteine-glucosamine) kits.  The 60-patient trial study is being conducted in the U.S.

Today, slightly greater than 6 million nuclear cardiology perfusion imaging scans are performed in the U.S. annually. Such procedures, referred to as myocardial perfusion imaging (MPI), are performed using either single photon emission computed tomography (SPECT) or positron emission tomography (PET) camera systems. SPECT MPI procedures represent 98 percent of the total. All MPI procedures, regardless of the choice of radiopharmaceutical agent, are designed to illuminate the healthy perfused part of the heart. A high percentage of the patients are required to undergo a time-consuming rest and separate stress study. While there are several cardiovascular disease indicators that can be looked at with MPI, the predominant focus for such studies is the presence, location and severity of myocardial ischemia following a heart attack.  

99mTc-Oncardia is not a perfusion agent. It is being clinically studied as the first functional cardiovascular imaging agent that is target-specific for myocardial ischemia.  One of the clinical objectives of the study is to demonstrate that 99mTc-Oncardia can be effectively used where the patient does not need to be either physically or pharmacologically stressed for the study.

99mTc-Oncardia is for use with SPECT camera systems. CellPoint also is planning to clinically study 68Ga-Oncardia for use with PET camera systems.

For more information: www.cellpointweb.com

Related Content

 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm
EchoGo uses artificial intelligence (AI) to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

EchoGo uses artificial intelligence (AI) to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

News | Cardiovascular Ultrasound | November 14, 2019
November 14, 2019 — Ultromics has received 510(k) clearance from the U.S.
An image on Brigham and Women's Hospital's 7T MRI system

An image on Brigham and Women's Hospital's 7T MRI system. Image courtesy of Brigham and Women's Hospital

News | Magnetic Resonance Imaging (MRI) | November 13, 2019
November 13, 2019 — Increased immune system activity along the surface of the brain, or meningeal inflammation, may b
Image by Dr. Manuel González Reyes from Pixabay

Image by Dr. Manuel González Reyes from Pixabay 

News | SPECT Imaging | November 08, 2019
November 8, 2019 — Using ground-breaking technology, researchers at the...
This chest X-ray of a patient being treated for e-cigarette or vaping-associated lung injury shows lung opacities, densities and whitish cloud-like areas which are typically seen with unusual pneumonias, fluid in lungs or lung inflammation. Image courtesy of Intermountain Healthcare

This chest X-ray of a patient being treated for e-cigarette or vaping-associated lung injury shows lung opacities, densities and whitish cloud-like areas which are typically seen with unusual pneumonias, fluid in lungs or lung inflammation. Image courtesy of Intermountain Healthcare

News | Clinical Trials | November 08, 2019
November 8, 2019 — As the outbreak of lung injuries and deaths associated with e-cigarettes, or...
Unlike other technologies for imaging the placenta, pCASL MRI can distinguish maternal blood from fetal blood

Image courtesy of Pixabay

News | Clinical Trials | November 07, 2019
November 7, 2019 — A new imaging technique to track
Philips Medical System is recalling its older Forte Gamma Camera SPECT imaging systems due to the possibility of the detectors falling off of the unit onto the patient. The two gamma cameras can bee seen in this photo on either side of the patient bed. These can be rotated above the patient.

Philips Medical System is recalling its older Forte Gamma Camera SPECT imaging systems due to the possibility of the detectors falling off of the unit onto the patient. The two gamma cameras can be seen in this photo on either side of the patient bed. These can be rotated above the patient.

Feature | Nuclear Imaging | November 05, 2019 | Dave Fornell, Editor
November 5, 2019 — Philips Medical System is recalling the Forte Gamma Camera System due to the potential for the 660
The Neuroreader software program quantifies brain volume in study participants with TBI

The Neuroreader software program quantifies brain volume in study participants with TBI. Image courtesy of UCLA Health.

News | Clinical Trials | October 29, 2019
October 29, 2019 — A UCLA-led...
 Phoenix’s fusion neutron generation technology.
News | Radiopharmaceuticals and Tracers | October 28, 2019
October 28, 2019 — Phoenix LLC and Shine Medical Technologies LLC, nuclear technology companies focused on near-term